Literature DB >> 20663457

Proposed clinical application for tuning fuzzy logic controller of artificial pancreas utilizing a personalization factor.

Richard Mauseth1, Youqing Wang, Eyal Dassau, Robert Kircher, Donald Matheson, Howard Zisser, Lois Jovanovic, Francis J Doyle.   

Abstract

BACKGROUND: Physicians tailor insulin dosing based on blood glucose goals, response to insulin, compliance, lifestyle, eating habits, daily schedule, and fear of and ability to detect hypoglycemia.
METHOD: We introduce a method that allows a physician to tune a fuzzy logic controller (FLC) artificial pancreas (AP) for a particular patient. It utilizes the physician's judgment and weighing of various factors. The personalization factor (PF) is a scaling of the dose produced by the FLC and is used to customize the dosing. The PF has discrete values of 1 through 5. The proposed method was developed using a database of results from 30 University of Virginia/Padova Metabolic Simulator in silico subjects (10 adults, 10 adolescents, and 10 children). Various meal sizes and timing were used to provide the physician information on which to base an initial dosing regimen and PF. Future decisions on dosing aggressiveness using the PF would be based on the patient's data at follow-up.
RESULTS: Three examples of a wide variation in diabetes situations are given to illustrate the physician's thought process when initially configuring the AP system for a specific patient.
CONCLUSIONS: Fuzzy logic controllers are developed by encoding human expertise into the design of the controller. The FLC methodology allows for the real-time scaling of doses without compromising the integrity of the dosing rules matrix. The use of the PF to individualize the AP system is enabled by the fuzzy logic development methodology. 2010 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663457      PMCID: PMC2909525          DOI: 10.1177/193229681000400422

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  4 in total

1.  Symmetrization of the blood glucose measurement scale and its applications.

Authors:  B P Kovatchev; D J Cox; L A Gonder-Frederick; W Clarke
Journal:  Diabetes Care       Date:  1997-11       Impact factor: 19.112

2.  Safety constraints in an artificial pancreatic beta cell: an implementation of model predictive control with insulin on board.

Authors:  Christian Ellingsen; Eyal Dassau; Howard Zisser; Benyamin Grosman; Matthew W Percival; Lois Jovanovic; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

3.  In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes.

Authors:  Boris P Kovatchev; Marc Breton; Chiara Dalla Man; Claudio Cobelli
Journal:  J Diabetes Sci Technol       Date:  2009-01

4.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

  4 in total
  15 in total

1.  Stress Testing of an Artificial Pancreas System With Pizza and Exercise Leads to Improvements in the System's Fuzzy Logic Controller.

Authors:  Richard Mauseth; Sandra M Lord; Irl B Hirsch; Robert C Kircher; Don P Matheson; Carla J Greenbaum
Journal:  J Diabetes Sci Technol       Date:  2015-09-14

2.  Inpatient trial of an artificial pancreas based on multiple model probabilistic predictive control with repeated large unannounced meals.

Authors:  Fraser Cameron; Günter Niemeyer; Darrell M Wilson; B Wayne Bequette; Kari S Benassi; Paula Clinton; Bruce A Buckingham
Journal:  Diabetes Technol Ther       Date:  2014-09-26       Impact factor: 6.118

3.  Identification of Main Factors Explaining Glucose Dynamics During and Immediately After Moderate Exercise in Patients With Type 1 Diabetes.

Authors:  Najib Ben Brahim; Jerome Place; Eric Renard; Marc D Breton
Journal:  J Diabetes Sci Technol       Date:  2015-10-18

4.  Artificial Intelligence Methodologies and Their Application to Diabetes.

Authors:  Mercedes Rigla; Gema García-Sáez; Belén Pons; Maria Elena Hernando
Journal:  J Diabetes Sci Technol       Date:  2017-05-25

5.  Stabilized glucagon formulation for bihormonal pump use.

Authors:  Solomon S Steiner; Ming Li; Robert Hauser; Roderike Pohl
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

6.  A controlled study of the effectiveness of an adaptive closed-loop algorithm to minimize corticosteroid-induced stress hyperglycemia in type 1 diabetes.

Authors:  Joseph El Youssef; Jessica R Castle; Deborah L Branigan; Ryan G Massoud; Matthew E Breen; Peter G Jacobs; B Wayne Bequette; W Kenneth Ward
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

7.  Multi-level Supervision and Modification of Artificial Pancreas Control System.

Authors:  Jianyuan Feng; Iman Hajizadeh; Xia Yu; Mudassir Rashid; Kamuran Turksoy; Sediqeh Samadi; Mert Sevil; Nicole Hobbs; Rachel Brandt; Caterina Lazaro; Zacharie Maloney; Elizabeth Littlejohn; Louis H Philipson; Ali Cinar
Journal:  Comput Chem Eng       Date:  2018-02-10       Impact factor: 3.845

8.  Clinical evaluation of an automated artificial pancreas using zone-model predictive control and health monitoring system.

Authors:  Rebecca A Harvey; Eyal Dassau; Wendy C Bevier; Dale E Seborg; Lois Jovanovič; Francis J Doyle; Howard C Zisser
Journal:  Diabetes Technol Ther       Date:  2014-01-28       Impact factor: 6.118

9.  Fabrication of a Flexible Amperometric Glucose Sensor Using Additive Processes.

Authors:  Xiaosong Du; Christopher J Durgan; David J Matthews; Joshua R Motley; Xuebin Tan; Kovit Pholsena; Líney Árnadóttir; Jessica R Castle; Peter G Jacobs; Robert S Cargill; W Kenneth Ward; John F Conley; Gregory S Herman
Journal:  ECS J Solid State Sci Technol       Date:  2015-02-18       Impact factor: 2.070

10.  Challenges and Recent Progress in the Development of a Closed-loop Artificial Pancreas.

Authors:  B Wayne Bequette
Journal:  Annu Rev Control       Date:  2012-12       Impact factor: 6.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.